Command Palette

Search for a command to run...

REMUS

660.05-3.56%
Market Cap
₹806.50 Cr
Stock P/E
27.74
ROCE
21.89%
ROE
18.58%
Book Value
₹222.13

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

POSITIVES
NEGATIVES

Peers Summary

Growth Outperformer

Remus Pharmaceuticals Ltd. stands out among its peers with robust efficiency metrics, specifically a high ROE, while maintaining a low debt-to-equity ratio. This positions it as a growth outperformer despite its currently undefined valuation metrics. However, compared to peers, it shows potential for strong performance if growth metrics improve. In contrast, companies like MMTC are showing significant financial distress.

Key Points
  • Remus Pharmaceuticals has a high ROE (29.91%) and low debt-equity ratio (0.1329).
  • Aditya Infotech leads in EPS (29.97) but carries a high PE ratio (107.99).
  • MMTC shows severe revenue decline indicating financial instability.
Top Performers
Remus Pharmaceuticals Ltd.

High efficiency ratios and low debt levels.

Redington Ltd.

Strong revenue growth and decent profitability metrics.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.